The National Institute for health and care excellence (NICE) has recommended Mylotarg (gemtuzumab ozogamicin), from Pfizer, for previously untreated, de...
Pfizer Inc. announced that the European Commission has approved Mylotarg (gemtuzumab ozogamicin) in combination with daunorubicin and cytarabine for the...
The FDA has approved Mylotarg (gemtuzumab ozogamicin), from Pfizer, for the treatment of adults with newly diagnosed acute myeloid leukemia...
Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
MYLOTARG is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL) (see sections 4.4 and 5.1).
This randomized phase III trial is studying combination chemotherapy and gemtuzumab to see how well they work compared with combination chemotherapy alone in treating young patients with newly diagnosed acute myeloid leukemia.